The CDSCO is considering a proposal to let hospitals directly import high-end medical devices like MRI and CT scanners. While intended to speed up technology access, domestic manufacturers fear potential safety and service risks. The move could reshape procurement dynamics for hospital chains and established equipment distributors.
What Happened
The Central Drugs Standard Control Organisation (CDSCO), India's primary drug and medical device regulator, is considering a significant shift in how hospitals acquire advanced medical equipment. A new proposal suggests allowing hospitals to directly import high-end diagnostic and therapeutic devices, potentially bypassing the traditional route of using licensed importers.
The preliminary plan covers a list of 80 specific items, including complex machinery such as MRI scanners, CT scanners, PET-CT systems, and mammography units. Currently, these items require hospitals to go through a rigorous import licensing process overseen by the regulator, similar to the requirements placed on commercial medical device distributors.
Why This Matters For Hospitals and Distributors
For major hospital chains, this move could lead to faster procurement times and potentially lower acquisition costs by removing middlemen from the supply chain. If hospitals can import directly, they may gain more flexibility in updating their technology to the latest global standards without waiting for distributor-led compliance cycles.
However, this shift creates uncertainty for companies that currently operate as the primary importers and distributors of these high-value machines. If a significant portion of the market moves to a direct-import model, the revenue streams of these specialized importers could be disrupted. Additionally, it forces hospital management teams to take on roles they typically outsource, such as handling complex import compliance and long-term service agreements.
The Safety and Regulatory Debate
Industry representatives, including the Association of Indian Manufacturers of Medical Devices (AiMeD), have raised concerns about the proposal. The core of their argument lies in the classification of the equipment involved. These are often categorized as Class C and Class D devices, which are considered high-risk equipment that requires specialized installation, regular calibration, and technical maintenance to ensure patient safety.
Manufacturers argue that licensed importers are mandated to maintain quality verification and after-sales support systems, which are essential for such sophisticated machinery. The industry concern is that if hospitals import directly, there may be gaps in technical expertise, maintenance, and compliance with local safety standards, potentially creating operational risks for the medical facilities themselves.
Business Impact and Risks
If the policy is implemented, it creates a dual-layered impact. On the positive side, it could drive faster adoption of medical innovation across private and public healthcare institutions. On the negative side, it introduces new risks: hospitals might face increased operational costs for service and maintenance if they lose the bundled support typically provided by authorized distributors.
Furthermore, for domestic manufacturers, this could signal a change in the competitive landscape. If foreign manufacturers begin to prioritize direct hospital channels over local distribution partners, the influence of established supply chains may decrease.
What To Watch Next
The most important factor for investors to monitor is the final notification from the CDSCO regarding which devices are included and what (if any) new compliance requirements will be placed on hospitals to ensure patient safety.
Investors should also watch for industry feedback on the current proposal, as the government is soliciting input from stakeholders. Changes to the final list of 80 items or the introduction of mandatory technical qualification standards for hospitals will dictate whether this move is a seamless transition or a regulatory hurdle for the healthcare sector.